Soleno Therapeutics, Inc. (FRA:6XC)

Soleno Therapeutics Statistics

Total Valuation

FRA:6XC has a market cap or net worth of EUR 2.26 billion. The enterprise value is 1.83 billion.

Market Cap	2.26B
Enterprise Value	1.83B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	53.71M
Shares Outstanding	n/a
Shares Change (YoY)	+28.16%
Shares Change (QoQ)	+8.79%
Owned by Insiders (%)	1.38%
Owned by Institutions (%)	122.90%
Float	52.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.93
PB Ratio	5.37
P/TBV Ratio	5.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-27.40
EV / Sales	21.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-82.92

Financial Position

The company has a current ratio of 16.08, with a Debt / Equity ratio of 0.11.

Current Ratio	16.08
Quick Ratio	15.77
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	-2.03
Interest Coverage	-19.34

Financial Efficiency

Return on equity (ROE) is -20.66% and return on invested capital (ROIC) is -12.92%.

Return on Equity (ROE)	-20.66%
Return on Assets (ROA)	-11.75%
Return on Invested Capital (ROIC)	-12.92%
Return on Capital Employed (ROCE)	-14.87%
Revenue Per Employee	553,294
Profits Per Employee	-439,888
Employee Count	92
Asset Turnover	0.22
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.36% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.36%
50-Day Moving Average	48.66
200-Day Moving Average	56.82
Relative Strength Index (RSI)	44.07
Average Volume (20 Days)	235

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.65

Income Statement

In the last 12 months, FRA:6XC had revenue of EUR 84.10 million and -66.86 million in losses. Loss per share was -1.38.

Revenue	84.10M
Gross Profit	82.54M
Operating Income	-71.82M
Pretax Income	-66.86M
Net Income	-66.86M
EBITDA	-70.11M
EBIT	-71.82M
Loss Per Share	-1.38

Balance Sheet

The company has 425.24 million in cash and 44.88 million in debt, giving a net cash position of 429.06 million.

Cash & Cash Equivalents	425.24M
Total Debt	44.88M
Net Cash	429.06M
Net Cash Per Share	n/a
Equity (Book Value)	421.72M
Book Value Per Share	7.85
Working Capital	427.51M

Cash Flow

In the last 12 months, operating cash flow was -22.07 million and capital expenditures -19,603, giving a free cash flow of -22.09 million.

Operating Cash Flow	-22.07M
Capital Expenditures	-19,603
Free Cash Flow	-22.09M
FCF Per Share	n/a

Margins

Gross margin is 98.14%, with operating and profit margins of -85.40% and -79.50%.

Gross Margin	98.14%
Operating Margin	-85.40%
Pretax Margin	-79.50%
Profit Margin	-79.50%
EBITDA Margin	-83.36%
EBIT Margin	-85.40%
FCF Margin	n/a

Dividends & Yields

FRA:6XC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-28.16%
Shareholder Yield	-28.16%
Earnings Yield	-2.95%
FCF Yield	-0.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 26, 2022. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	Aug 26, 2022
Split Type	Reverse
Split Ratio	0.0666666667

Scores

FRA:6XC has an Altman Z-Score of 16.62 and a Piotroski F-Score of 1.

Altman Z-Score	16.62
Piotroski F-Score	1